Biorestorative Therapies, Inc. · NASDAQ:BRTX
Biorestorative Therapies — Investor Presentation (April 2026)
37 slides from Biorestorative Therapies's investor presentation, Apr 23, 2026
Slide 1: Regenerative Biology for Healthier Lives
biorestorat\|ve therapies Regenerative Biology for Healthier Lives Corporate Presentation April 2026 NASDAQ: BRTX
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements in this presentation, including the information set forth as to the future financial or operating performance of BioRestorative Therapies, Inc. (the “Company”) that are not current or historical factual statements may constitute “forward-looking” information wit
Slide 3: About BioRestorative
About BioRestorative Clinical-stage regenerative medicine company developing advanced cell-base therapies using adult stem cell and tissue protocols for spine disorders, metabolic disease, and regenerative aesthetics. Disc/Spine Late-Stage Clinical Program BRTX-100, late-stage Phase 2 development of
Slide 4: Investment Highlights
Investment Highlights Late-Stage Clinical Asset with Regulatory Momentum * BRTX-100 (late Phase 2 full enrolled) for chronic lumbar disc disease * FDA Fast Track designation * Spring 2027 topline clinical data expected Near-Term Commercialization of Regenerative Biologics Platform + BioCosmeceutical
Slide 5: Mid-Stage Clinical: ThermoStem, BRTX-100, BioCosmeceuticals
MID-STAGE CLINICAL | ThermoStem BRTX-100 BioCosmeceuticals Source: Secretome Source: Source: ; ; < novel exosome, growth Brown adipose-derived Bone marrow-derived { f g p actor/cytokine) stem Cells mesenchymal stem cells | biologics-based technology for cosmetic applications Application: Obesi oe 2
Slide 6: Robust Preclinical & Clinical Pipeline
Robust Preclinical & Clinical Pipeline AUTOLOGOUS ALLOGENEIC PRECLINICAL PHASE! PHASE2 PHASE 3 COMMERCIAL Lumbar i Spine Conia Thoracic [ Hips/Knees [ a Extremities an Avascular Zones . Type 2 Diabetes . Metabolic Obesity . Brown Adipose ARDS ea Stemicells Long Hauler Covid f bi creator
Slide 7: Chronic Lumbar Disc Disease (cLDD) U.S. adult population
Chronic Lumbar Disc Disease (cLDD) 258 M U.S. adult population 64.5 M iswerback pain provaience. 32 M American adults with diagnosed and treated disc degeneration 15 M Americans suffering pain caused by a protruding or injured disc 2 5 M Invasive Surgical Procedures per e year; $40 billion in surger
Slide 8: The Problem: Clinical & Economic
The Problem: Clinical & Economic Medical Surgical Treatments Treatments Ste ortciie Gemmanaad \ i SPINAL FUSION SURGERY $1,000 - $2,000 4, y $110,000 INJECTION TREATMENT R.. - DISCECTOMY $8,000 jan UNMET NEED $20,000 - oa ieserercee eeseea RR CEE CHER $50,000 PHYSICAL MEASURES al ™* DISC REPLACEMENT
Slide 9: Our Solution: BRTX-100
Our Solution: BTRX-100 Conservative Treatments ORAL MEDICATION TREATMENT J opioips $1,000 - $2,000 ........, INJECTION TREATMENT $8,000 erway $2,000 per injection, 2 injections per treatment-semi-annual treatment PHYSICAL MEASURES $20,000 | .nuary $200 per session, 2 sessions per week Often Recurren
Slide 10: BRTX-100: Technical Overview - Logistical/Clinical Process
BRTX-100: Technical Overview - Logistical /Clinical Process 10 Collection Collection and Shipment of Patient's Bone Marrow and Blood to Cell Production Manufacturer Clinical Site Production Thawing and Injection of Production of BRTX-100 Hypoxic BRTX-100 into Patient's Disc BRTX-100 Culturing of Ste
Slide 11: BRTX-100 in cLDD: Phase 2 Trial Design
BRTX-100 in cLDD: Phase 2 Trial Design FDA Cleared IND 17275: Phase 2 Randomized, Controlled Study Design in Patients with cLDD Design * Study includes 105 subjects (2:1 product to placebo) * 40,000,000 cells/dose + Included subjects will have only one symptomatic diseased disc Primary Efficacy Endp
Slide 12: Compelling Preliminary Phase 2 Clinical Data
12 Compelling Preliminary Phase 2 Clinical Data (36 Subjects): Meaningful Signals 80% 60% 40% 20% 0% 52 weeks mmm Average improvement in VAS versus baseline mmm Average improvement in ODI versus baseline ——Level of improvement required by the FDA Presented at ISSCR 2025 FDA is requiring at least a g
Slide 13: New ORS 2026 Blinded Data: Sustained Efficacy Across Endpoint Scales
New Phase 2 ORS 2026 Blinded Data: Sustained Efficacy Across Endpoint Scales 13 Percentage of patients achieving >50% improvement over time. 100% 80% 60% 40% 20% 0% 100% 80% 60% 40% 20% 0% 53.57% 57.14% 26w (n=28) VAS (Pain Intensity) 75.00% RMDQ (Spinal Disability) 50.00% 52w (n=12) 75.00% 104w (n=
Slide 14: The Convergence Standard: Simultaneous Pain and Function Relief
The Convergence Standard: Simultaneous Pain and Function Relief 14 ORS 2026 Blinded Data Percentage of Patients Achieving >50% Improvement in BOTH ODI and VAS 100% At two years post- treatment, 57% of 80% evaluated patients maintained a >50% reduction in pain while Al% simultaneously experiencing a
Slide 15: BRTX-100: Key Differentiating Factors
BRTX-100: Key Differentiating Factors 15 SOURCE CULTURING CARRIER MANUFACTING Retclogous Hypoxic cultured Autologous Platelet Bicrestorctive ee eee am in low oxygen Lysate Carrier & 100% Animal-Free 40 million environment (5%) Adjuvant Allogeneic uses human derived Normoxic cultured Smesoblast stem
Slide 16: BioCosmeceuticals
a BioCosmeceuticals Source: Secretome (novel exosome, growth factor/cytokine) biologics-based technology for cosmetic applications Application: Biologics- based technology for regenerative cosmetic applications
Slide 17: BioRestorative's Cell-based Therapeutics And Biocosmeceuticals
BioRestorative’s Cell-based Therapeutics And Biocosmeceuticals biorestoraive 7 Biox-HR Delivers regenerative biosignals that assist healthy hair growth cycles Cellular Effect Intensity BioX-1 Optimized formulation that delivers essential benefits of exosome science in a balanced, accessible concentr
Slide 18: BRTX-C: Market Dynamics
BRTX-C: Market Dynamics The Skincare Market Is Being Disrupted Three macro forces are colliding: Biotech-led prestige Proof-driven consumer Regenerative mainstreaming Exosomes, stem cell signaling, “Clean” and “natural” have Prestige brands are no longer PRP, and biologics are now been replaced by c
Slide 19: Uncompromised purity
Uncompromised purit' refined to pharmaceutical | isolation, purification, and final giegs siemslencks _ formulation is documented, _ verified, and auditable. / Quality y Manufactured under a rc System and rel quality standards, d traceability, exceed typical iorestordt|ve »
Slide 20: Commercializing Regenerative Biologics in Aesthetic Markets
Commercializing Regenerative Biologics in Aesthetic Markets 20 Advancing into High-Growth Regenerative Aesthetics Markets The Market + Global Cosmetic market $63B and growing + Global Regenerative market $42B(2024) est $154B(2033) + Regenerative products are the new standard + Market filled with pro
Slide 21: BRTX-C: Going Commercial
BRTX-C: Going Commercial 21 Our Approach Aesthetic Regenerative Direct to Distributors Distributors Consumer Early Progress Identified multiple high-quality opportunities and are in advanced closing discussions Global skincare manufacturer | High profile celebrity provider Beauty supplier expanding
Slide 22: ThermoStem
J ThermoStem Source: Brown adipose-derived 4 stem cells : Application: | | Obesity, Type 2 diabetes, metabolic disorders a.
Slide 23: ThermoStem Program: Allogeneic Cell-based Therapy
ThermoStem Program: Allogeneic Cell-based Therapy 23 Target Conditions: Obesity, Type 2 diabetes, and Metabolic disorders Cell Type: Brown Fat * Has been shown to regulate metabolic homeostasis in the body Components of Library: + Human Brown Adipose Tissue (BAT) * White Adipose Tissue (WAT) * Brown
Slide 24: Metabolic Program Highlights
Metabolic Program Highlights First human stem cell derived BAT transfer lie WHITE FAT f OK Pi iF BEIGE FAL SEBEL Ip, : adh Ay She * Creation of first human 3D engineered artificial brown adipose tissue construct (aBAT) Successful delivery of 3D aBAT construct in mouse model Transplantation of aBAT l
Slide 25: File DMF with FDA / Initiate Phase 1/2 Clinical Trial
File DMF with FDA Expect filing a Drug Master File (“DMF”) with the FDA to facilitate licensing opportunities around ThermosStem. Initiate Phase 1/2 Clinical Trial Pre-IND Meeting Upon FDA approval commence with FDA Phase 1/2 clinical trial. Scheduling Pre-IND meeting with FDA to discuss first-in-ma
Slide 26: Our Opportunities are Well-Protected
Our Opportunities are Well-Protected 26 NO. OF PROGRAM INDICATION PATENT TITLES STATUS APPLICATIONS ThermoStem Disc / Spine Metabolic Methods and Compositions to facilitate repair of avascular tissue Surgical Methods and Compositions to & facilitate repair of avascular tissue Therapeutic Delivery De
Slide 27: Near Term Catalysts
Near Term Catalysts 27 PROGRAM BRTX-100 Phase 2 2027 & BEYOND Enrollment Complete Clinical data presented at ORS 2026 2027 (Q2) - 1-Year Data Clinical data presented at ISCT 2026 2028 (Q2) - 1-Year Follow-up Publish blinded BRTX-100 clinical data File IND for allogeneic (off-the-shelf) BRTX-100 BRTX
Slide 28: Recent Accomplishments
Recent Accomplishments ¥Y Completed enrollments in Phase 2 BRTX-100 clinical trial ca eee ¥ Announced commercial biocosmeceutical agreement with Cartessa__ v Received expanded tissue license from New York State Dept. of Health 28 Announced FDA clearance of important BRTX-100 clinical study protocol
Slide 29: Key Metrics
Key Metrics Common Shares Outstanding 25.5 Million* Cash $ 7.95 Million** Debt $0 Warrants Outstanding 19,780,753 Million * As of 03/26/2026 ** As of 12/31/2025 year end, add $5.0 million gross proceeds from Rodman deal of Feb 2026 29 biorestoratlve
Slide 30: Experienced Leadership
Experienced Leadership 30 Lance Alstodt Chairman & CEO + 30+ years leading, advising and operating companies within the Healthcare sector + Founder, MedVest Capital, (a Healthcare investment fund created in 2013) + Former head of Medical Technology investment banking group at JP Morgan, BAML and Lee
Slide 31: In Conclusion
In Conclusion 31 CGMP ISO-7 Certified Clean room Addressing Multi-Billion Dollar Markets with Unmet Needs Disruptive Platform Technologies in Cellular Therapy Opportunity for Key Strategic Partnerships in Cosmetic Space Strong Preliminary Data Indicative of Positive Trial Outcomes Strong Intellectua
Slide 32: plorentorcive
plorentorcive therapies 40 Marcus Drive, Suite 1 Melville, NY 11747 (631) 760-8100 biorestorative.com
Slide 33: Appendix
Appendix 33 therapies
Slide 34: BRTX-100: Positive Human Data
BRTX-100: Positive Human Data 34 and an absence of significant safety issues with a durable response conan nae __ Journal of Translational Medicine Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety
Slide 35: BRTX-100: Cleared DSMB June 2023
BRTX-100: Cleared DSMB June 2023 35 Unanimous approval by the DSMB to continue trial without changes 3:1 randomization BRTX-100 is safe and well tolerated No Significant Adverse Events All 4 subjects successfully dosed with either 40 mil NMSCs or placebo VAS, ODI, SF-12, RMDQ, and FRI scores to meas
Slide 36: BRTX-100: Clinical Snapshot
BRTX-100: Clinical Snapshot Lead investigational therapeutic product 0 LY e Autologous Hypoxic (low oxygen) Single intradiscal injection (patient’s own) cultured, bone - anticipated 30 minute cell-based biologic marrow-derived in-office procedure * ow) lil a ilil Prior human data provides Ongoing FD
Slide 37: Scientific Advisory Board
Scientific Advisory Board 37 Wayne Marasco, MD, PDt Chairman of SAB + Principal Faculty Member of Harvard Stem Cell Institute + Professor in the Department of Cancer Immunology & AIDS at the Dana-Farber Cancer Institute + Professor of Medicine at Harvard Medical School Wayne Olan, MD Clinical Direct
BioRestorative Therapies — Investor Presentation (April 2026) on 6ix